Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies
Open accessThe DOI matches its Crossref record; 288 of the 295 references it cites were found in a registry or an index.
Abstract
Melanoma is a highly aggressive cancer with the poorest prognosis, representing the deadliest form of skin cancer. Activating mutations in BRAF are the most frequent genetic alterations, present in approximately 50% of all melanoma cases. The use of specific inhibitors towards mutant BRAF variants and MEK, a downstream signaling target of BRAF in the MAPK pathway, has significantly improved progression-free and overall survival in advanced melanoma patients carrying BRAF mutations. Nevertheless, despite these improvements, resistance still develops within the first year of therapy in around 50% of patients, which is a significant problem in managing BRAF-mutated advanced melanoma. Understanding these mechanisms is one of the mainstreams of the research on BRAFi/MEKi acquired resistance. Both genetic and epigenetic mechanisms have been described. Moreover, in recent years, oxidative stress has emerged as another major force involved in all the phases of melanoma development, from initiation to progression until the onsets of the metastatic phenotype and chemoresistance, and has thus become a target for therapy. In the present review, we discuss the current knowledge on oxidative stress and its signaling in melanoma, as well as the oxidative stress-related mechanisms in the acquired resistance to targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“There is overwhelming evidence that oxidative stress plays a central role in the different stages of melanomagenesis [ 72 , 73 ].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 201–288 of 288
Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma
Yue, L., Huang, Z., Fong, S., Leong, S. P. L., Jakowatz, J. G., Charruyer, A., Wei, M. L., & Ghadially, R. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000144 · Cited by 60
ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating Cells
Sarvi, S., Crispin, R., Lu, Y., Zeng, L., Hurley, T. D., Houston, D. R., von Kriegsheim, A., Chen, C.-H., Mochly-Rosen, D., Ranzani, M., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.09.005 · Cited by 58
Kreuzer, T., Grube, R., Wutte, A., Žarković, N., & Schaur, R. J. (1998) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00029-x · Cited by 57
Pérez‐Alea, M., McGrail, K., Sánchez‐Redondo, S., Fábrega, B. F., Fournet, G., Cortés, J., Muñoz‐Couselo, E., Hernández‐Losa, J., Tenbaum, S. P., Martin, G., et al. (2017) · Oncogene · doi:10.1038/onc.2017.160 · Cited by 57
Paclitaxel-Loaded Nanosponges Inhibit Growth and Angiogenesis in Melanoma Cell Models
Clemente, N., Argenziano, M., Gigliotti, C. L., Ferrara, B., Boggio, E., Chiocchetti, A., Caldera, F., Trotta, F., Benetti, E., Annaratone, L., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00776 · Cited by 57
Self-citationProduction of superoxide by human malignant melanoma cells
Bittinger, F., Gonz??lez-Garc??a, J. L., Klein, C. L., Brochhausen, C., Offner, F., & Kirkpatrick, C. J. (1998) · Melanoma Research · doi:10.1097/00008390-199810000-00001 · Cited by 56
Effect of 4-Hydroxynonenal on c-myc Expression
Barrera, G., Martinotti, S., Fazio, V. M., Manzari, V., Paradisi, L., Parola, M., Frati, L., & Dianzani, M. U. (1987) · Toxicologic Pathology · doi:10.1177/019262338701500219 · Cited by 56
Self-citationDiaconeasa, Z. M., Ayvaz, H., Rugină, D. O., LEOPOLD, L. F., Stănilă, A., Socaciu, C., Tăbăran, F., Lupuţ, L., Mada, D. C., Pintea, A., et al. (2017) · Plant Foods for Human Nutrition · doi:10.1007/s11130-017-0638-x · Cited by 56
Hintsala, H., Jokinen, E., Haapasaari, K., Moza, M., Ristimaki, A. P., Soini, Y., Koivunen, J. P., & Karihtala, P. (2016) · PubMed · Cited by 54
4-Hydroxynonenal and transforming growth factor-β1 expression in colon cancer
Zanetti, D., Poli, G., Vizio, B., Zingaro, B., Chiarpotto, E., & Biasi, F. (2003) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(03)00022-0 · Cited by 53
Jin, N., Zhu, X., Cheng, F., & Zhang, L. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26885 · Cited by 52
The Role of Peroxiredoxin Family in Cancer Signaling
Kim, Y., & Jang, H. H. (2019) · Journal of Cancer Prevention · doi:10.15430/jcp.2019.24.2.65 · Cited by 52
Audrito, V., Managò, A., Gaudino, F., & Deaglio, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.001 · Cited by 51
Jessen, C., Kreß, J. K. C., Baluapuri, A., Hufnagel, A., Schmitz, W., Kneitz, S., Roth, S., Marquardt, A., Appenzeller, S., Ade, C. P., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01535-1 · Cited by 51
Epigenetic Regulation in Melanoma: Facts and Hopes
Giunta, E. F., Arrichiello, G., Curvietto, M., Pappalardo, A., Bosso, D., Rosanova, M., Diana, A., Giordano, P., Petrillo, A., Federico, P., et al. (2021) · Cells · doi:10.3390/cells10082048 · Cited by 51 · cited 1×
“DNA methylation pattern at individual CpG sites [29], post-translational modifications of histones, and noncoding RNA deregulation have been demonstrated to be involved [30].”
BackgroundWang, M., Shi, G., Bian, C., Nisar, M. F., Guo, Y., Wu, Y., Li, W., Huang, X., Jiang, X., Bartsch, J. W., et al. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/9742154 · Cited by 49
Antony, S., Jiang, G., Wu, Y., Meitzler, J. L., Makhlouf, H. R., Haines, D. C., Butcher, D. O., Hoon, D. S. �., Ji, J. J., Zhang, Y., et al. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22708 · Cited by 48
Association Between Oxidative Stress and Melanoma Progression
Bisevac, J. P., Djukic, M. M., Stanojević, I., Stevanović, I. D., Mijušković, Ž. P., Djurić, A., Gobeljić, B., Banovic, T., & Vojvodić, D. (2017) · Journal of Medical Biochemistry · doi:10.1515/jomb-2017-0040 · Cited by 47
Goodson, A. G., Cotter, M. A., Cassidy, P., Wade, M., Florell, S. R., Liu, T., Boucher, K. M., & Grossman, D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1890 · Cited by 46
Bracalente, C., Ibañez, I. L., Berenstein, A., Notcovich, C., Cerda, M. B., Klamt, F., Chernomoretz, A., & Durán, H. (2106) · Oncotarget · doi:10.18632/oncotarget.9273 · Cited by 46
Schmitt, A., Schmitz, W., Hufnagel, A., Schartl, M., & Meierjohann, S. (2015) · Biochemical Journal · doi:10.1042/bj20141204 · Cited by 45
Shadows of NRF2 in cancer: Resistance to chemotherapy
Choi, B.-H., & Kwak, M. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.08.003 · Cited by 45
Ibarrola-Villava, M., Martin-Gonzalez, M., Lazaro, P., Pizarro, A., Lluch, A., & Ribas, G. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.10831.x · Cited by 44
4-Hydroxynonenal Specifically Inhibits c-myb but Does Not Affect c-fos Expressions in HL-60 Cells
Barrera, G., Pizzimenti, S., Serra, A., Ferretti, C., Fazio, V. M., Saglio, G. N., & Dianzani, M. U. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1550 · Cited by 42
Self-citationEmerging Strategies in Systemic Therapy for the Treatment of Melanoma
Ascierto, P. A., Flaherty, K. T., & Goff, S. L. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199047 · Cited by 42 · cited 3×
“Not only are MAPK and PI3K pathways upregulated in resistant melanoma cells, but so are their upstream receptor tyrosine kinases (RTKs), such as the Erb-B2 receptor tyrosine kinase 3 (ERBB3), the insulin-like growth factor (IGF)-1 receptor, the hepatocyte growth factor receptor (c-MET), the epidermal growth factor rec…”
BackgroundInfluentialWoźniak, A., Drewa, G., Woźniak, B., & Schachtschabel, D. O. (2004) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-004-0229-y · Cited by 41
Jenkins, S. V., Robeson, M. S., Griffin, R. J., Quick, C. M., Siegel, E. R., Cannon, M. J., Vang, K. B., & Dings, R. P. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-4108 · Cited by 41
Jia, J., Parikh, H. M., Xiao, W., Hoskins, J. W., Pflicke, H., Liu, X., Collins, I. J., Zhou, W., Wang, Z., Powell, J. I., et al. (2013) · BMC Medical Genomics · doi:10.1186/1755-8794-6-33 · Cited by 41
Non-Melanoma Skin Cancer: news from microbiota research
Squarzanti, D. F., Zavattaro, E., Pizzimenti, S., Amoruso, A., Savoia, P., & Azzimonti, B. (2020) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2020.1794792 · Cited by 40
Self-citationJuric-Sekhar, G., Zarkovic, K., Waeg, G., Cipak, A., & Zarkovic, N. (2009) · Tumori Journal · doi:10.1177/030089160909500620 · Cited by 40
The Effects of Nrf2 on Tumor Angiogenesis: A Review of the Possible Mechanisms of Action
Zhou, S., Ye, W., Zhang, M., & Liang, J. (2012) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v22.i2.60 · Cited by 40
Lipid peroxidation in hepatomas of different degrees of deviation
Rossi, M. A., & Cecchini, G. (1983) · Cell Biochemistry and Function · doi:10.1002/cbf.290010109 · Cited by 40
Nuclear 8-hydroxy-2'-deoxyguanosine as survival biomarker in patients with cutaneous melanoma
Sirigu (2009) · Oncology Reports · doi:10.3892/or_00000640 · Cited by 39
Recent Advances in Phenolic Metabolites and Skin Cancer
Pop, T. D., & Diaconeasa, Z. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189707 · Cited by 39
de Melo, F. H. M., Molognoni, F., Morais, A. S., Toricelli, M., Mouro, M. G., Higa, E. M. S., Lopes, J. D., & Jasiulionis, M. G. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.02.022 · Cited by 38
Miura, S., Shibazaki, M., Kasai, S., Yasuhira, S., Watanabe, A., Inoue, T., Kageshita, Y., Tsunoda, K., Takahashi, K., Akasaka, T., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.343 · Cited by 37
Inhibition of host NOX1 blocks tumor growth and enhances checkpoint inhibitor–based immunotherapy
Stalin, J., Garrido‐Urbani, S., Heitz, F., Szyndralewiez, C., Jemelin, S., Coquoz, O., Rüegg, C., & Imhof, B. A. (2019) · Life Science Alliance · doi:10.26508/lsa.201800265 · Cited by 37
Grattarola, M., Cucci, M. A., Roetto, A., Dianzani, C., Barrera, G., & Pizzimenti, S. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.08.006 · Cited by 37
Self-citationSuresh, A., Guedez, L., Moreb, J., & Zucali, J. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04074.x · Cited by 36
Redox Modulation of FAK Controls Melanoma Survival - Role of NOX4
Ribeiro-Pereira, C., Moraes, J. A., Souza, M. D. J., Laurindo, F. R., Arruda, M. A., & Barja-Fidalgo, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099481 · Cited by 35
Development of a Novel Multi-Isoform ALDH Inhibitor Effective as an Antimelanoma Agent
Dinavahi, S. S., Gowda, R., Gowda, K., Bazewicz, C. G., Chirasani, V. R., Battu, M. B., Berg, A. S., Dokholyan, N. V., Amin, S., & Robertson, G. P. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0360 · Cited by 35
Bioactivation of luteolin by tyrosinase selectively inhibits glutathione S-transferase
Balyan, R., Kudugunti, S. K., Hamad, H. A., Yousef, M. S., & Moridani, M. Y. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.08.011 · Cited by 34
Matsuzaki, T., Yokokura, T., & Azuma, I. (1987) · Cancer Immunology Immunotherapy · doi:10.1007/bf00205585 · Cited by 34
Hsiao, Y., Tsai, C., Wu, P.-P., Hsu, S., Liu, H., Huang, Y., Yang, J., & Chung, J. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2689 · Cited by 34
Polyphenolic Nutraceuticals to Combat Oxidative Stress Through Microbiota Modulation
Vamanu, E. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00492 · Cited by 34
Mutual dependence of growth modifying effects of 4-hydroxynonenal and fetal calf serum in vitro
Žarković, N., Schaur, R. J., Puhl, H., Jurin, M., & Esterbauer, H. (1994) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(94)90208-9 · Cited by 33
Yuan, L., Mishra, R., Patel, H. M., Alanazi, S., Wei, X., Ma, Z., & Garrett, J. T. (2020) · Cancers · doi:10.3390/cancers12061661 · Cited by 33
Prasad, R., Kappes, J. C., & Katiyar, S. K. (2016) · Oncotarget · doi:10.18632/oncotarget.6860 · Cited by 32
Deguelin induces the apoptosis of lung cancer cells through regulating a ROS driven Akt pathway
Xu, H., Li, X., Ding, W., Zeng, X., Kong, H., Wang, H., & Xie, W. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0166-4 · Cited by 32
What Is New in Melanoma Genetics and Treatment?
Ribero, S., Longo, C., Glass, D., Nathan, P., & Bataille, V. A. (2016) · Dermatology · doi:10.1159/000445767 · Cited by 31
Self-citationCarpenter, E. L., Chagani, S., Nelson, D., Cassidy, P. B., Laws, M. E., Ganguli‐Indra, G., & Indra, A. K. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23068 · Cited by 31
Inhibition of Melanoma B16-F10 Growth by Lipid Peroxidation Product 4-Hydroxynonenal
Žarković, N., Tillian, M., Schaur, J. R., Waeg, G., Jurin, M., & Esterbauer, H. (1995) · Cancer Biotherapy · doi:10.1089/cbr.1995.10.153 · Cited by 30
Luca, A. D., Rotili, D., Carpanese, D., Lenoci, A., Calderan, L., Scimeca, M., Mai, A., Bonanno, E., Rosato, A., Geroni, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2798 · Cited by 30
Kumari, V., Dyba, M., Holland, R. J., Liang, Y., Singh, S. V., & Ji, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163821 · Cited by 30
Dietary antioxidants and melanoma: Evidence from cohort and intervention studies
Miura, K., & Green, A. C. (2015) · Nutrition and Cancer · doi:10.1080/01635581.2015.1053499 · Cited by 29
Quantitative Differential Proteome Analysis in an Animal Model for Human Melanoma
Lokaj, K., Meierjohann, S., Schutz, C. N., Teutschbein, J., Schartl, M., & Sickmann, A. (2009) · Journal of Proteome Research · doi:10.1021/pr800578a · Cited by 29
Chen, H., Zheng, Z., Kim, K., Jin, X., Roh, M. R., & Jin, Z. (2016) · Oncology Reports · doi:10.3892/or.2016.5071 · Cited by 29
Pleiotropic Effects of Biguanides on Mitochondrial Reactive Oxygen Species Production
Pecinová, A., Drahota, Z., Kovalcikova, J., Kovářová, N., Pecina, P., Alán, L., Zima, M., Houštěk, J., & Mráček, T. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/7038603 · Cited by 29
Hämäläinen, M., Teppo, H., Skarp, S., Haapasaari, K., Porvari, K., Vuopala, K. S., Kietzmann, T., & Karihtala, P. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/2647068 · Cited by 29
Treatment of Advanced Metastatic Melanoma
Quaglino, P., Fava, P., Tonella, L., Rubatto, M., Ribero, S., & Ferro, M. T. (2021) · Dermatology Practical & Conceptual · doi:10.5826/dpc.11s1a164s · Cited by 29
Self-citationFurther Experiments on Lipid Peroxidation in Transplanted and Experimental Hepatomas
Dianzani, M. U., Canuto, R. A., Rossi, M. A., Poli, G., Garcea, R., Biocca, M. E., Cecchini, G., Biasi, F., Ferro, M., & Bassi, A. M. (1984) · Toxicologic Pathology · doi:10.1177/019262338401200213 · Cited by 27
Kreuzer, T., Žarković, N., Grube, R., & Schaur, R. J. (1997) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.1997.12.131 · Cited by 26
Wang, X., Dong, H.-S., Li, Q., Li, Y., & Hong, A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1027471 · Cited by 25
Canuto, R. A., Muzio, G., Biocca, M. E., & Mu, D. (1989) · Cancer Letters · doi:10.1016/0304-3835(89)90208-5 · Cited by 25
Self-citationClinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes
Samson, J. M., Menon, D. R., Smith, D. E., Baird, E., Kitano, T., Gao, D., Tan, A. C., & Fujita, M. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108822 · Cited by 24
Markovic, S. N., Suman, V. J., Javed, A., Reid, J. M., Wall, D. J., Erickson, L. A., Ernstoff, M. S., & Anderson, D. M. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000644 · Cited by 24
Genotyping of cutaneous melanoma.
Glitza, I. C., & Davies, M. A. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.03.01 · Cited by 22 · cited 1×
“Several other non-MAPK pathway dysregulations have been described in BRAFi/MEKi resistance, such as the copy number variations of cyclin D1 and cyclin-dependent kinase inhibitor p16INK4A and the inactivation of retinoblastoma (Rb) protein [27,28].”
BackgroundNrf2 Deficiency Promotes Melanoma Growth and Lung Metastasis
Zhu, H., Jia, Z., Trush, M. A., & Li, Y. R. (2016) · doi:10.20455/ros.2016.853 · Cited by 22
Gao, Y., Zhao, Z., Meng, X., Chen, H., & Fu, G. (2018) · Oncology Letters · doi:10.3892/ol.2018.8799 · Cited by 22
Post-translational inhibition of YAP oncogene expression by 4-hydroxynonenal in bladder cancer cells
Cucci, M. A., Compagnone, A., Daga, M., Grattarola, M., Ullio, C., Roetto, A., Palmieri, A., Rosa, A. C., Argenziano, M., Cavalli, R., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.06.009 · Cited by 21
Self-citationSládek, N. E., Dockham, P. A., & Lee, M. O. (1990) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-5901-2_12 · Cited by 20
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications
Kudlowitz, D., & Muggia, F. M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.910193 · Cited by 20
FAM129B‐dependent activation of NRF2 promotes an invasive phenotype in BRAF mutant melanoma cells
Schmidlin, C. J., Tian, W., Dodson, M. B., Chapman, E., & Zhang, D. D. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23295 · Cited by 20
Pizzimenti, S., Ciamporcero, E. S., Pettazzoni, P., Osella‐Abate, S., Novelli, M., Toaldo, C., Husse, M., Daga, M., Minelli, R., Bisazza, A., et al. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.035 · Cited by 19
Self-citationAbility of different hepatoma cells to metabolize 4‐hydroxynonenal
Canuto, R. A., Muzio, G., Maggiora, M., Poli, G., Biasi, F., Mu, D., Ferro, M., Bassi, A. M., Penco, S., & Marinari, U. M. (1993) · Cell Biochemistry and Function · doi:10.1002/cbf.290110202 · Cited by 18
Self-citationNanomedicine in Melanoma: Current Trends and Future Perspectives
El-Kenawy, A. E.-M., Constantin, C., Hassan, S. M. A., Mostafa, A., Neves, A. F., Araújo, T. G., & Neagu, M. T. (2017) · Codon Publications eBooks · doi:10.15586/codon.cutaneousmelanoma.2017.ch10 · Cited by 18
Hwang, K., Park, D., Kim, Y. S., Kim, B.-R., Park, S. N., Lee, M., Park, S., Yoon, K., Jeong, E., & Kim, H.-R. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1918 · Cited by 17
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
Queirolo, P., Spagnolo, F., Picasso, V., Spano, L., Tanda, E. T., Fontana, V., Giorello, L., Merlo, D. F., Simeone, E., Grimaldi, A. M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10589 · Cited by 13
Hintsala, H., Haapasaari, K., Soini, Y., & Karihtala, P. (2017) · PubMed · doi:10.14670/hh-11-778 · Cited by 12
Melanoma metastases caught in the AKT
Kircher, D. A., Arave, R. A., Cho, J. H., & Holmen, S. L. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1128516 · Cited by 9
Pizzimenti, S., Daga, M., Ciamporcero, E. S., Toaldo, C., Pettazzoni, P., Osella‐Abate, S., Novelli, M., Minelli, R., Bisazza, A., Gamba, P., et al. (2015) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2015.2131 · Cited by 9
Self-citationEfficacy of nab-paclitaxel in treating metastatic melanoma
Specenier, P. M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1569628 · Cited by 8
Blendea, A., Serban, I. L., Branisteanu, D. C., & Brănișteanu, D. (2017) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.1000364 · Cited by 6
4-Hydroxynonenal Metabolism by Aldo/Keto Reductase in Hepatoma Cells
Muzio, G., Salvo, R. A., Taniguchi, N., Maggiora, M., & Canuto, R. A. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4735-8_55 · Cited by 5 · cited 10×
“GSTs are a family of detoxification enzymes able to conjugate reduced GSH to a wide number of exogenous and endogenous electrophilic and hydrophobic substrates, participating in tumorigenic processes and drug resistance [169].”
BackgroundInfluentialSelf-citationAldehyde dehydrogenase isozymes: markers of cancer stem cells in human melanoma
Nguyen, N. D., Luo, Y., & Fujita, M. (2013) · Expert Review of Dermatology · doi:10.1586/edm.13.2 · Cited by 4
Mario Umberto Dianzani’s scientific legacy
Poli, G. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.01.002 · Cited by 1
Research Article Intestinal Dysbiosis Increases the Incidence of Malignant Melanoma in Mice Model
Ren, X., Zhang, X., Zhu, Y., Gamallat, Y., Meyiah, A., Ma, S., & Xin, Y. (2017) · Genetics and Molecular Research · doi:10.4238/gmr16039840 · Cited by 1
Dianzani, U. (1997) · PubMed · Cited by 1
Research works printed but not linked: 1
- Gracia-Sancho, J., and Salvadó, J. (2017). Oxidative Stress and Gut Microbiota. Gastrointestinal Tissue Oxidative Stress and Dietary Antioxidant, Academic Press. Chapter 8.
Cited by
Emanuelli, M., Sartini, D., Molinelli, E., Campagna, R., Pozzi, V., Salvolini, E., Simonetti, O., Campanati, A., & Offidani, A. (2022) · Antioxidants · doi:10.3390/antiox11040612 · Cited by 132
“Indeed, oxidative stress has emerged as an important player in all stages of melanoma, from genesis to progression until the development of the metastatic disease and chemoresistance, thus being a promising pathway for targeted therapy [18,19].”
BackgroundAir pollution and skin diseases: A comprehensive evaluation of the associated mechanism.
Gu, X., Li, Z., & Su, J. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116429 · Cited by 91
Oxidative Stress and Age-Related Tumors
Carlo, E. D., & Sorrentino, C. (2024) · Antioxidants · doi:10.3390/antiox13091109 · Cited by 112
“UV-induced oxidative stress is a major cause of skin cancers, including melanoma [196] and non-melanoma skin cancers [197].”
BackgroundOxidative Stress and Skin Diseases: The Role of Lipid Peroxidation
Pomi, F. L., Gammeri, L., Borgia, F., Gioacchino, M. D., & Gangemi, S. (2025) · Antioxidants · doi:10.3390/antiox14050555 · Cited by 100
“The pharmacological inhibition of GPX4 or the depletion of its cofactor, glutathione, leads to the accumulation of oxidized lipid species, ultimately triggering ferroptosis [86].”
Attri, N., Das, S., Banerjee, J., Shamsuddin, S. H., Dash, S. K., & Pramanik, A. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c00153 · Cited by 67
Metadata
- Authors
- Pizzimenti, S., Ribero, S., Cucci, M. A., Grattarola, M., Monge, C., Dianzani, C., Barrera, G., & Muzio, G.
- Affiliations
- University of Turin (IT)
- Department of Clinical and Biological Science, University of Turin, 10125 Turin, Italy
- Corresponding author
- Pizzimenti, Stefania
- ORCID
- Venue
- Antioxidants
- Publisher
- MDPI AG
- Published
- 2021-12-03
- Volume
- 10
- Issue
- 12
- Pages
- 1942
- ISSN
- 2076-3921 (ISSN-L)
- PMC
- PMC8750393
- OpenAlex
- W4200547360
- Cited by
- 79
- References
- 295
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 14 · 2023: 21 · 2022: 13
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Antioxidants (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Dipartimenti di Eccellenza (Dipartimenti di Eccellenza 2018-2022, 2018–2022, D15D18000410001)
- Ministero dell’Istruzione, dell’Università e della Ricerca (20182022, D15D18000410001, “Dipartimenti di Eccellenza - 2018-2022”)
- Università degli Studi di Torino (2019.2252, D15D18000410001)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- melanoma, oxidative stress, acquired drug resistance, BRAF inhibitors, MEK inhibitors, BRAF mutation, MAPK signaling, epigenetic mechanisms, chemoresistance, metastasis, antioxidant signaling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.